Dr Salazar talks to ecancertv at ASCO 2014 about the results of the CALGB/SWOG 80405 study which suggest that the four common first-line treatment regimens – bevacizumab plus chemotherapy and cetuximab plus chemotherapy – are equally effective for patients with metastatic colorectal cancer and no KRAS mutations.

Read the article or watch the press conference for more.